• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.

作者信息

Călugăru Dan, Călugăru Mihai

机构信息

Department of Ophthalmology, University of Medicine Cluj-Napoca/Romania, Cluj-Napoca, Romania.

出版信息

Graefes Arch Clin Exp Ophthalmol. 2017 Jul;255(7):1451-1452. doi: 10.1007/s00417-017-3669-y. Epub 2017 Apr 7.

DOI:10.1007/s00417-017-3669-y
PMID:28389701
Abstract
摘要

相似文献

1
Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.将治疗方案从贝伐单抗转换为阿柏西普以治疗持续性糖尿病性黄斑水肿。
Graefes Arch Clin Exp Ophthalmol. 2017 Jul;255(7):1451-1452. doi: 10.1007/s00417-017-3669-y. Epub 2017 Apr 7.
2
Re: Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.关于：将治疗从贝伐单抗转换为阿柏西普用于持续性糖尿病黄斑水肿的管理。
Graefes Arch Clin Exp Ophthalmol. 2017 Jul;255(7):1453-1454. doi: 10.1007/s00417-017-3670-5. Epub 2017 Apr 8.
3
Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.将治疗方案从贝伐单抗转换为阿柏西普以治疗持续性糖尿病性黄斑水肿。
Graefes Arch Clin Exp Ophthalmol. 2017 Jun;255(6):1133-1140. doi: 10.1007/s00417-017-3624-y. Epub 2017 Feb 25.
4
Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.阿柏西普治疗既往贝伐单抗治疗无效的糖尿病性黄斑水肿：治疗结果及成功预测因素
Graefes Arch Clin Exp Ophthalmol. 2018 Jan;256(1):83-89. doi: 10.1007/s00417-017-3836-1. Epub 2017 Oct 29.
5
Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.阿柏西普用于曾接受雷珠单抗和/或贝伐单抗治疗的糖尿病性黄斑水肿眼，可能会进一步改善黄斑厚度。
Ophthalmic Surg Lasers Imaging Retina. 2016 Sep 1;47(9):836-9. doi: 10.3928/23258160-20160901-06.
6
Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema.既往抗血管内皮生长因子治疗持续性糖尿病黄斑水肿后改用阿柏西普治疗
Am J Ophthalmol. 2016 Aug;168:290-291. doi: 10.1016/j.ajo.2016.05.015. Epub 2016 Jun 4.
7
Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.阿柏西普治疗既往贝伐单抗治疗无效的糖尿病性黄斑水肿：疗效及成功预测因素
Graefes Arch Clin Exp Ophthalmol. 2018 Jul;256(7):1353-1354. doi: 10.1007/s00417-018-3951-7. Epub 2018 Mar 9.
8
Short-Term Effects of Early Switching to Ranibizumab or Aflibercept in Diabetic Macular Edema Cases With Non-Response to Bevacizumab.在对贝伐单抗无反应的糖尿病性黄斑水肿病例中早期改用雷珠单抗或阿柏西普的短期效果
Ophthalmic Surg Lasers Imaging Retina. 2017 Mar 1;48(3):230-236. doi: 10.3928/23258160-20170301-06.
9
Short-Term Outcomes of Aflibercept Therapy for Diabetic Macular Edema in Patients With Incomplete Response to Ranibizumab and/or Bevacizumab.阿柏西普治疗对雷珠单抗和/或贝伐单抗反应不完全的糖尿病性黄斑水肿患者的短期疗效
Ophthalmic Surg Lasers Imaging Retina. 2015 Oct;46(9):950-4. doi: 10.3928/23258160-20151008-08.
10
Reply to the letter to the editor: Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.致编辑的信的回复：阿柏西普治疗既往贝伐单抗治疗无效的糖尿病性黄斑水肿：治疗结果及成功预测因素
Graefes Arch Clin Exp Ophthalmol. 2018 Jul;256(7):1355-1356. doi: 10.1007/s00417-018-3952-6. Epub 2018 Mar 10.

引用本文的文献

1
Romanian ophthalmologists in the renowned ophthalmic journals worldwide.罗马尼亚眼科医生发表于全球知名眼科期刊上的文章。 （原英文表述不太完整准确，推测完整意思应该是类似这样，若按照字面翻译是：罗马尼亚眼科医生在全球著名眼科期刊里）
Rom J Ophthalmol. 2018 Oct-Dec;62(4):260-269.
2
Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.阿柏西普治疗既往贝伐单抗治疗无效的糖尿病性黄斑水肿：疗效及成功预测因素
Graefes Arch Clin Exp Ophthalmol. 2018 Jul;256(7):1353-1354. doi: 10.1007/s00417-018-3951-7. Epub 2018 Mar 9.
3
Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice.

本文引用的文献

1
Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.将治疗方案从贝伐单抗转换为阿柏西普以治疗持续性糖尿病性黄斑水肿。
Graefes Arch Clin Exp Ophthalmol. 2017 Jun;255(6):1133-1140. doi: 10.1007/s00417-017-3624-y. Epub 2017 Feb 25.
2
Real-World Outcomes of Ranibizumab Treatment for Diabetic Macular Edema in a United Kingdom National Health Service Setting.在英国国家医疗服务体系中，雷珠单抗治疗糖尿病性黄斑水肿的真实世界疗效
Am J Ophthalmol. 2017 Feb;174:175-176. doi: 10.1016/j.ajo.2016.10.013. Epub 2016 Nov 25.
3
Comments to: Ranibizumab for persistent diabetic macular edema after bevacizumab treatment.
阿柏西普治疗具有临床意义的糖尿病性黄斑水肿：日常临床实践中的12个月结果
Clin Ophthalmol. 2018 Jan 8;12:99-104. doi: 10.2147/OPTH.S154421. eCollection 2018.
4
Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment.
Graefes Arch Clin Exp Ophthalmol. 2018 May;256(5):1035-1037. doi: 10.1007/s00417-018-3901-4. Epub 2018 Jan 20.
致编辑的信：贝伐单抗治疗后雷珠单抗用于持续性糖尿病黄斑水肿
Eur J Ophthalmol. 2017 May 11;27(3):e104-e105. doi: 10.5301/ejo.5000898.
4
Comments to: Long-term efficacy and safety of intravitreal dexamethasone implant for the treatment of diabetic macular edema.致：玻璃体内注射地塞米松植入物治疗糖尿病性黄斑水肿的长期疗效和安全性的评论
Eur J Ophthalmol. 2016 Nov 4;26(6):e171-e172. doi: 10.5301/ejo.5000869.
5
Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema.既往抗血管内皮生长因子治疗持续性糖尿病黄斑水肿后改用阿柏西普治疗
Am J Ophthalmol. 2016 Aug;168:290-291. doi: 10.1016/j.ajo.2016.05.015. Epub 2016 Jun 4.
6
TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations.视网膜疾病中抗血管内皮生长因子（VEGF）药物的治疗与延长方案：文献综述与共识建议
Retina. 2015 Aug;35(8):1489-506. doi: 10.1097/IAE.0000000000000627.
7
Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab.VEGF 陷阱、雷珠单抗和贝伐珠单抗与血管内皮生长因子（VEGF）及其相关配体的结合和中和作用。
Angiogenesis. 2012 Jun;15(2):171-85. doi: 10.1007/s10456-011-9249-6.
8
Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (spectralis).高清光谱域光学相干断层扫描（Spectralis）测量黄斑厚度的正常参考值。
Am J Ophthalmol. 2009 Aug;148(2):266-71. doi: 10.1016/j.ajo.2009.03.006. Epub 2009 May 9.